At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,756 enrolled
Drug / intervention
Nitazoxanide +1 moredrug
Likely dose
Nitazoxanide 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
In Brief
A Phase 3 clinical trial evaluating Nitazoxanide and Placebo for Enterovirus and Rhinovirus. Completed, enrolled 1,756 participants across 45 sites in 2 countries.
Detailed Summary
Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnterovirus, Rhinovirus
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartSep 2018
Primary CompletionFeb 2019
TodayJul 2026
First PostedJul 30, 2018
Enrollment StartSep 11, 2018
Primary CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.9 years ago
Interventions
Nitazoxanidedrug
Nitazoxanide 600 mg administered orally twice daily for five days
Placebodrug
Placebo administered orally twice daily for five days